These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 11205197

  • 1. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
    Sun SS, Hsieh JF, Tsai SC, Ho YJ, Kao CH.
    Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
    [Abstract] [Full Text] [Related]

  • 2. Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
    Lee JK, Tsai SC, Hsieh JF, Ho YJ, Sun SS, Kao CH.
    Anticancer Res; 2000; 20(6C):4765-8. PubMed ID: 11205215
    [Abstract] [Full Text] [Related]

  • 3. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
    Tai CJ, Liu FY, Liang JA, Yang SN, Tsai MH, Kao CH.
    Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
    [Abstract] [Full Text] [Related]

  • 4. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
    Lin WY, Yen TC, Cheng KY, Wang SJ.
    Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
    [Abstract] [Full Text] [Related]

  • 5. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC, Shiau YC, Chang WC, Kao CH, Lin CC.
    Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
    [Abstract] [Full Text] [Related]

  • 6. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
    Chang CH, Wu HC, Yen RF, Kao A, Lin CC, Lee CC.
    Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
    [Abstract] [Full Text] [Related]

  • 7. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.
    Wei YS, Zheng YH, Liang WB, Zhang JZ, Yang ZH, Lv ML, Jia J, Zhang L.
    Cancer; 2008 Feb 01; 112(3):544-51. PubMed ID: 18085639
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
    Molina R, Torres MD, Moragas M, Filella X, Jo J, Giménez N, Traserra J, Ballesta AM.
    Anticancer Res; 1995 Feb 01; 15(2):479-84. PubMed ID: 7763026
    [Abstract] [Full Text] [Related]

  • 9. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
    Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D.
    Cancer; 1999 Mar 01; 85(5):1018-25. PubMed ID: 10091783
    [Abstract] [Full Text] [Related]

  • 10. Serum tissue polypeptide specific antigen (TPS) in patients with cervical carcinoma: preliminary report.
    Pattaranutaporn P, Chansilpa Y, Tangkarat S, Tepmongkol P, Sangruchi S, Senapad S.
    Anticancer Res; 1997 Mar 01; 17(3C):2309-12. PubMed ID: 9216707
    [Abstract] [Full Text] [Related]

  • 11. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
    Padungsutt P, Thirapagawong C, Senapad S, Suphanit I.
    Anticancer Res; 2000 Mar 01; 20(2B):1291-5. PubMed ID: 10810437
    [Abstract] [Full Text] [Related]

  • 12. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
    Gitsch G, Kainz C, Joura E, Fröhlich B, Bieglmayr C, Tatra G.
    Anticancer Res; 1992 Mar 01; 12(4):1247-9. PubMed ID: 1503417
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [The value of marker antigens TPS, SCC and CEA in diagnosis, evaluation of histologic type and clinical disease progression in patients with cervical carcinoma].
    Zakrzewska I.
    Pol Merkur Lekarski; 2001 Jan 01; 10(55):21-3. PubMed ID: 11320545
    [Abstract] [Full Text] [Related]

  • 16. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 17. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
    Kulpa J, Wójcik E, Radkowski A, Kolodziejski L, Stasik Z.
    Anticancer Res; 2000 Mar 15; 20(6D):5035-40. PubMed ID: 11326663
    [Abstract] [Full Text] [Related]

  • 18. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A.
    Cancer; 2002 Nov 01; 95(9):1886-93. PubMed ID: 12404282
    [Abstract] [Full Text] [Related]

  • 19. Serum tissue polypeptide specific antigen (TPS) in locoregional failure and distant metastasis of cervical carcinoma.
    Pattaranutaporn P, Chansilpa Y, Ieumwananonthachai N, Sukkasem M.
    J Med Assoc Thai; 2000 Sep 01; 83(9):1011-5. PubMed ID: 11075966
    [Abstract] [Full Text] [Related]

  • 20. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R, Menezes J, Drouet E, Joab I, Benider A, Bakkali H, Kanouni L, Jouhadi H, Benjaafar N, El Gueddari B, Hassar M, Khyatti M.
    J Clin Virol; 2008 Feb 01; 41(2):96-103. PubMed ID: 18024156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.